Market Place
Sourcing Support
Vivet Presents Gene Therapy Data for Cerebrotendinous Xanthomatosis
14 Nov 2024 //
GLOBENEWSWIRE
Vivet Presents Posters On Cerebrotendinous Xanthomatosis At ESGCT
22 Oct 2024 //
GLOBENEWSWIRE
Europe Grants Orphan Drug Designation for Vivet`s Gene Therapy for CTX
05 Sep 2024 //
PR NEWSWIRE
Vivet Doses First Patient in Ph 1/2 GATEWAY Clinical Trial
08 Apr 2024 //
PR NEWSWIRE
Vivet receives EUR 4.9 million to advance development of a gene therapy
01 Feb 2024 //
PR NEWSWIRE
Vivet Therapeutics Announces Presentations at Upcoming ESGCT
23 Oct 2023 //
GLOBENEWSWIRE
Vivet Therapeutics’ VTX-801 gets FDA fast track designation for Wilson disease
12 Aug 2021 //
PHARMABIZ
Vivet Therapeutics’ VTX-801 gets FDA fast track designation for Wilson disease
12 Aug 2021 //
PHARMABIZ
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803
10 May 2021 //
GLOBENEWSWIRE
Mirum and Vivet Enter into Exclusive Worldwide Option and License Agreement
13 Apr 2021 //
GLOBNEWSWIRE
Vivet & Pfizer Manufacturing Agreement for Vivet’s Investigational Gene Therapy
22 Sep 2020 //
BUSINESSWIRE
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US, EuropeanODD
01 Jun 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.